Hyperkalemia
Conditions
Keywords
Healthy Chinese Subjects, Pharmacodynamic Study
Brief summary
This is a single center, inpatient, open label pharmacodynamic study to determine the effect of 5 g and 10 g doses of Sodium Zirconium Cyclosilicate (ZS) administered once daily (qd) for 4 days on potassium and sodium excretion in healthy Chinese subjects on a standardized, low sodium and high potassium diet.
Detailed description
This study will be conducted at 1 study centre in Hong Kong. Approximately 22 Subjects will be screened to achieve 20 subjects completing the study. Subjects will be randomized to receive ZS 5 g or 10 g (1:1) once daily (qd) in conjunction with breakfast and will be continued with a standard diet during the ZS treatment period.
Interventions
Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures 2. Female and/or male healthy Chinese subjects aged between 18 and 55 inclusive who reside in Hong Kong 3. Ability to have repeated blood draws or effective venous catheterization 4. Willing to consume food and beverages using a standardized daily diet containing 40 (± 10%) mEq/day sodium and 128 (± 10%) mEq/day potassium provided by the research site Key
Exclusion criteria
1. Participation in another clinical study with an investigational product during the last 3 months 2. Subjects who were receiving concomitant medications including vitamins, dietary supplements and herbal preparations within 2 weeks prior to Study Day 1 of the Diet Run-in Period. 3. Current and/or past history of alcohol abuse within the past year or a positive results (exceed normal range) of breath test for alcohol abuse 4. Current and/or past history of drugs abuse within the past year or a positive drug abuse screen, e. g. methylenedioxymethamphetamine, opiate, barbiturates, benzodiazepines, ketamine, cocaine, amphetamine, methamphetamine, marijuana, and methadone. 5. Plasma donation within 1 month of screening or any blood donation/blood loss \>500 mL during the 3 months prior to screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change from baseline to ZS treatment period in urine potassium excretion. | Study Day 3 and 4 vs Study Day 7 and 8. | The 48- hour urine potassium excretion on Study Days 3 and 4 (baseline) will be compared with 48-hour urine potassium excretion on Study Days 7 and 8 (on study drug). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change from baseline to ZS treatment period in urine sodium excretion. | Study Day 3 and 4 vs Study Day 7 and 8. | The 48- hour urine sodium excretion on Study Days 3 and 4 (baseline) will be compared with 48- hour urine sodium excretion on Study Days 7 and 8 (on study drug). |
| Mean change from baseline to ZS treatment period in serum potassium (S-K). | Study Day 3 and 4 vs Study Day 7 and 8. | Mean change in S-K from the Baseline Period (Day 3 and 4) to the ZS Treatment Period (Day 7 and 8). |
Other
| Measure | Time frame |
|---|---|
| Changes in standard physical examination parameters including height | Through study completion, up to 10 days |
| Changes in standard clinical chemistry lab parameters | Through study completion, up to 10 days |
| Changes in standard hematology lab parameters | Through study completion, up to 10 days |
| Changes in Serum calcium (S-Ca) | Through study completion, up to 10 days |
| Changes in Serum magnesium (S-Mg) | Through study completion, up to 10 days |
| Number of subjects with adverse events | From Day 1 through Follow-up visit |
| Changes in Serum phosphate (S-PO4) | Through study completion, up to 10 days |
| Changes in Serum bicarbonate (S-HCO3) | Through study completion, up to 10 days |
| Changes in Blood urea nitrogen (BUN) | Through study completion, up to 10 days |
| Number of subjects with Serious adverse events | Through study completion and follow-up visit, up to 34 Days |
| Changes in Serum sodium (S-Na) | Through study completion, up to 10 days |
| Changes in vital signs | Through study completion, up to 10 days |
| Changes in standard Electrocardiograph (ECG ) parameters | Through study completion, up to 10 days |
Countries
Hong Kong
Outcome results
None listed